Senior-led pre-submission strategy for medical device, combination product, and biotech sponsors preparing for high-stakes FDA interactions.
Chosen for nearly two dozen FDA data-integrity audits.
Built for inspections, not just enrollment.
Decades guiding high‑stakes medtech and biotech programs.
A Q-Submission (Q-Sub) is the FDA’s main program for obtaining Agency feedback before a formal regulatory submission. Sponsors may request written feedback and, when appropriate, a meeting with the FDA before committing to a formal submission pathway.
It is voluntary, carries no user fee, and for many medical device and biotech programs, is one of the most valuable regulatory programs available, giving sponsors an opportunity to understand the FDA’s thinking/expectations, clarify questions, and refine regulatory strategy before significant time and resources are committed.
The challenge is that a Q-Sub only produces useful feedback when the right questions are asked, the supporting evidence is clearly structured, and the timing allows you to act on the FDA’s response.
Health Policy Associates (HPA) provides senior-led FDA pre-submission consulting for sponsors who want to use their Q-Sub as a genuine strategic tool, not a checkbox. We help you identify the right questions, build a defensible briefing package, and interpret the FDA’s response so your team walks away with a clear, executable plan.
The FDA has consistently encouraged sponsors to engage early, and the finalized 2025 Q-Sub guidance reinforces that early interaction with the Agency improves submission quality, reduces review delays, and facilitates the development process.
But early engagement only helps if the submission itself is well-structured. A strategic approach is important, which means the questions you choose to ask, and the totality of the evidence you present alongside them, determine whether you leave with actionable intelligence or generic guidance that doesn’t move the program forward.
HPA helps sponsors frame Q-Sub questions and strategies that surface the FDA’s current position and expectations on classification, pathway, evidence requirements, clinical study design, predicate strategy, and risk determination — and interpret feedback so nothing gets lost in translation.
The Q-Submission program includes several distinct submission types, each designed for a different stage of the regulatory process. HPA helps sponsors select the right type, structure the content, and prepare for the interaction.
The most common Q-Sub type. Pre-Submissions allow sponsors to request FDA feedback on planned submissions, testing strategies, clinical protocols, predicate device selection, and regulatory pathways before filing a formal application.
A well-timed Pre-Sub can clarify the FDA’s expectations early enough to reshape study design, evidence strategy, or classification decisions while there is still room to move.
Used to resolve specific technical or regulatory issues identified during the FDA’s active review of a pending submission, Submission Issue Requests (SIRs) can address review deficiencies faster than traditional amendment cycles, keeping the review moving rather than stalling on an unresolved question.
A focused Q-Sub to obtain an FDA determination on whether a planned clinical study qualifies as significant risk, nonsignificant risk, or exempt from IDE regulations. An incorrect risk determination can require a full IDE application that was not in the original plan, delay study start, or trigger enforcement actions.
HPA helps sponsors build the rationale and supporting evidence to present the study clearly to the FDA.
Informational Meetings give sponsors the opportunity to share new technology, updated data, or a revised development approach with the FDA without requesting formal written feedback. These meetings are typically used to educate a review division on a novel product concept or to reintroduce a technology after a significant change in approach.
For sponsors with Breakthrough Device Designation, the Q-Sub program provides a pathway for ongoing FDA interaction throughout development. PMA Day 100 Meetings allow sponsors to engage with the FDA approximately 100 days into the PMA review to discuss review progress and any emerging questions.
HPA supports both of these interactions with briefing content, question strategy, and meeting preparation.
When the stakes are high, HPA turns ambiguity into clear findings, prioritized risks and next steps, so your team stops debating in gray areas and starts moving with conviction.
HPA helps you make decisions and build evidence that holds up under FDA questioning—especially when data integrity, framing, or compliance concerns could derail your program.
Our senior-led team stays with you and manages scope changes transparently, so you avoid handoff drag, reduce rework, and control spend without the change-order spiral.
Every pre-submission engagement is shaped by where the sponsor is in development, what the FDA needs to see, and which questions will do the most work for the program. While scope varies, a typical Q-Sub engagement with HPA covers the following ground.
01
We evaluate your product’s current regulatory position to identify what the FDA is most likely to question and where your current narrative may have gaps.
We also review applicable FDA guidance, relevant regulations, prior Agency communications, and conduct literature reviews for the publicly available information to better understand the regulatory landscape and identify issues that may influence the FDA’s feedback.
And we help determine which Q-Sub type fits your situation, whether the timing is right, and whether a Pre-Sub is the best use of the interaction. When it is, we help you time it so the FDA’s feedback arrives while you still have meaningful flexibility in study design, evidence planning, or pathway positioning.
02
We develop focused, strategically sequenced questions designed to elicit the FDA’s substantive position on the decisions that will shape your submission, each supported by a rationale that gives the FDA enough context to respond specifically.
We then draft the briefing document to minimize the risk of raising unnecessary questions due to imprecise language, unsupported claims, or incomplete supporting information.
03
When a meeting is part of the pre-submission, we prepare your team with anticipated FDA questions, recommended responses, key discussion points, and a plan for handling unexpected pushback.
After the FDA’s written response arrives (typically within 70 days of acceptance), we help your team interpret the feedback, assess its implications for your regulatory and clinical strategy, and translate it into a prioritized action plan with clear next steps across functions.
Some programs need more than a standard pre-submission package. When the regulatory picture is particularly complex, we can extend the engagement to include the following.
A deeper assessment of the specific regulated submissions your program will need beyond the initial Q-Sub, including a more detailed mapping of IDE, 510(k), De Novo, PMA, and related variants, with sequencing and timing considerations that inform your development roadmap.
For products that sit at the device/biologic or device/drug boundary, classification and lead-center determination can fundamentally change the regulatory pathway and its cost.
We help sponsors frame Q-Sub questions that surface the FDA’s view on classification before the program commits to a direction that may carry significantly different timelines and budget implications.
If your internal team or another consultant has drafted the briefing package, we provide an in-depth review for strategy alignment, completeness, and language risk, including detailed redlines and alternative framing options where the current language may trigger unnecessary FDA scrutiny.
An expanded analysis of your testing, data, and documentation with a more granular plan to close gaps before the pre-submission, including recommended labs and vendors, timing and sequencing considerations, and high-level budget implications.
For sponsors transitioning from a European CE Mark to a U.S. IDE pathway, we compare your existing technical files and European data packages against U.S. IDE expectations and outline the additional work required, including what belongs in the Q-Sub versus the formal IDE application.
If your pre-submission work reveals the need for broader regulatory support, we can extend the engagement into Regulatory Consulting Services or Clinical Trial Strategy & Execution, so your regulatory, clinical, and quality efforts stay aligned from strategy through execution.
A Q-Sub is one of the critical steps in the regulatory process when you can ask the FDA what it thinks before committing your program to a particular direction.
The difference between a pre-submission that produces a usable roadmap and one that produces boilerplate feedback often comes down to how the questions are framed, how the evidence is presented, and whether the timing gives you room to act.
HPA brings senior-led, audit-grade regulatory judgment to your pre-submission so you can go into the FDA interaction prepared, get substantive feedback, and come out with a plan your team, leadership, and investors can stand behind.
